Provided by Tiger Trade Technology Pte. Ltd.

Cumberland Pharmaceuticals

7.65
+0.15002.00%
Post-market: 7.650.00000.00%19:30 EDT
Volume:34.80K
Turnover:260.82K
Market Cap:114.42M
PE:-10.34
High:7.65
Open:7.52
Low:7.34
Close:7.50
52wk High:8.45
52wk Low:1.85
Shares:14.96M
Float Shares:8.75M
Volume Ratio:0.38
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7398
EPS(LYR):-0.1909
ROE:-14.39%
ROA:-2.91%
PB:6.56
PE(LYR):-40.07

Loading ...

Cumberland Pharmaceuticals - Fewer Deaths Due to Metastasis in Ifetroban Arm Versus Placebo Arm

THOMSON REUTERS
·
Jun 02

Cumberland says Phase 2a trial shows ifetroban safe in high-risk solid tumors, signals fewer metastasis deaths

Reuters
·
Jun 02

Cumberland announces launch of Vibativ in China

TIPRANKS
·
May 28

Cumberland Pharmaceuticals partners with SciClone to commercialize Vibativ in China

Reuters
·
May 28

RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline and Talicia commercialization

Reuters
·
May 27

Cumberland Q1 FY26 swings to net loss of $3.29 million; net revenues fall 22.04% to $9.13 million

Reuters
·
May 09

Cumberland Pharmaceuticals Pivots After Transformational Apotex Deal

TIPRANKS
·
May 07

Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln

Reuters
·
May 06

Cumberland Pharmaceuticals Q1 Adjusted EPS USD -0.13

THOMSON REUTERS
·
May 06

Cumberland Pharmaceuticals Q1 FY26 net loss widens to $3.3 million; revenue falls 22% to $9.1 million

Reuters
·
May 06

Cumberland Q1 Adj. EPS $(0.13) Down From $0.16 YoY, Sales $9.131M Down From $11.713M YoY

Benzinga Earnings
·
May 06

Cumberland Pharmaceuticals Reports Q1 2026 Financial Results & Company Update

THOMSON REUTERS
·
May 06

RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline

Reuters
·
Apr 29

Cumberland Pharmaceuticals schedules Q1 results release and conference call

Reuters
·
Apr 29

Cumberland Pharmaceuticals shareholders approve Carr, Riggs & Ingram auditor appointment

Reuters
·
Apr 25

NASD Most Active Issues

Dow Jones
·
Apr 24

Cumberland Pharmaceuticals Inc - Termination Fee of $4 Mln Payable by Cumberland or Apotex Under Certain Conditions - SEC Filing

THOMSON REUTERS
·
Apr 23

Cumberland sells branded drug portfolio to Apotex for $100 million cash

Reuters
·
Apr 23

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business With Apotex

THOMSON REUTERS
·
Apr 23

Cumberland Pharmaceuticals Inc - Apotex to Buy Cumberland's Branded Pharmaceuticals for $100 Mln Cash

THOMSON REUTERS
·
Apr 23